- “A novel engineered protein therapeutic for treatment of lung adenocarcinoma” Cochran, Jennifer
- “Improving genome editing technologies to enable chimeric-antigen receptor macrophage (CHARM)-based cellular therapy in cancer” Bhatt, Ami; Bassik, Michael; Bintu, Lacramioara
- “Biomarkers of immune response in solid tumor patients treated with a novel checkpoint inhibitor combination” Chen, Chris; Satpathy, Ansuman
Funding Opportunities
Shmunis Family Innovation Awards in Cancer Therapeutics
Awardees
-
From inhibition to activation: A novel siglec-based strategy for cancer immunotherapy
Carolyn Bertozzi, PhD, Baker Family Director of Stanford ChEM-H, Anne T. and Robert M. Bass Professor in the School of Humanities and Sciences, was awarded a $50,000 Shmunis Family Innovation Award in Cancer Therapeutics for her project entitled “From inhibition to activation: A novel siglec-based strategy for cancer immunotherapy.”
-
Targeting hyperactive mTORC2 in lung cancer
Kacper Rogala, PhD, assistant professor of structural biology and of chemical and systems biology, was awarded a $50,000 Shmunis Family Innovation Award in Cancer Therapeutics for his proposal titled “Targeting hyperactive mTORC2 in lung cancer.”
-
Harnessing an E3 ligase for pancreatic cancer therapy
Steven Corsello, MD, Assistant Professor of Medicine (Oncology), was awarded a $50,000 Shmunis Family Innovation Awards in Cancer Therapeutics award for his project entitled “Harnessing an E3 ligase for pancreatic cancer therapy.”